With an impressive record to date of raising substantial capital, Biolinq is a startup having developed a proprietary wearable biosensor platform capable of measuring blood level information, without the need to draw blood. The firm's wearable biosensor platform is designed to measure biomarkers important to the management of many clinical conditions including diabetes. In effect, bringing nanotechnology to the medical arena, the effort has been to design a precision micro-array of biosensors to measure interstitial fluid glucose levels just under the surface of the skin - potentially a life-changing capability for those having, for exampls, diabetes: afforable and pain-free
